home / stock / cing / cing news

CING News and Press, Cingulate Inc. From 06/23/22

Stock Information
Company Name: Cingulate Inc.
Stock Symbol: CING
Market: NASDAQ
Website: cingulate.com
Menu
CING CING Quote CING Short CING News CING Articles CING Message Board
Get CING Alerts

News, Short Squeeze, Breakout and More Instantly...
CING - Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders

KANSAS CITY, Kan., June 23, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmac...
CING - Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., June 02, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmac...

CING - Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders

Active Pharmaceutical Ingredient – Buspirone – One of the Most Widely Prescribed Agents in $5.5B U.S. Anxiety Market, Which Must be Taken Multiple Times Daily CTx-2103 is the Third Candidate Using Cingulate’s Proprietary Precision Timed Release™ Drug ...

CING - Cingulate to Present at H.C. Wainwright Global Investment Conference

KANSAS CITY, Kan., May 18, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmace...
CING - Cingulate GAAP EPS of -$0.44

Cingulate press release (NASDAQ:CING): Q1 GAAP EPS of -$0.44. “At its core, Cingulate has maintained a primary focus on addressing patients’ suboptimal treatment outcomes and overcoming unmet needs due to the limitations of current standard of care treatments,” ...

CING - Cingulate Inc. Reports First Quarter 2022 Results and Provides Clinical and Business Update

KANSAS CITY, Kan., May 12, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmace...

CING - Cingulate (CING) NobleCon18 Presentation Replay

Cingulate (CING) formal corporate presentation from NobleCon18 - Noble Capital Markets 18th Annual Small & Microcap Investor Conference - April 2022. Read More >>

CING - Cingulate Presents at NobleCon18

KANSAS CITY, Kan., April 26, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharma...

CING - JNCE and RPID among healthcare movers

Gainers: Eiger BioPharmaceuticals (EIGR) +36%. Cyteir Therapeutics (CYT) +30%. PAVmed (PAVM) +28%. Cingulate (CING) +26%. Bone Biologics (OTCPK:BBLG) +22%. Losers: Incannex Healthcare Limited (IXHL) -12%. Jounce Therapeutics (JNCE) -9%. Rapid Micro Biosystems (RPID) -...

CING - Cingulate GAAP EPS of -$0.32

Cingulate press release (NASDAQ:CING): Q4 GAAP EPS of -$0.32. As of December 31, 2021, Cingulate had $16.5 million in cash and cash equivalents. Based on the Company’s current operating plan, Cingulate expects its cash and cash equivalents as of December 31, 2021 will enable the Compan...
Previous 10 Next 10